Compound ID | 1229
GSK-3342830, GSK3342830
Class: Beta-lactam (cephalosporin)
| Spectrum of activity: | Gram-negative |
| Details of activity: | Bacterial infection |
| Institute where first reported: | GlaxoSmithKline PLC (Shionogi licensee) |
| Highest developmental phase: | Phase 1 |
| Development status: | Discontinued |
| Reason Dropped: | Participants in Phase 1 clinical trial experienced headache, malaise, and/or fever, liver injury, and decrease in platelet count |
| External links: | |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.